Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ENGN with free AI briefings, catalyst countdowns, and dilution alerts.

ENGN · enGene Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$266.3M Cash on Hand
32.3mo Cash Runway
Follow ENGN by email Get an email when ENGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ENGN, unsubscribe in one click. Privacy

📣 What ENGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Detalimogene Voraplasmid (EG-70) Superficial Bladder Cancer Phase 1/2 · NCT04752722 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ENGN holds $266.3M in cash and short-term investments (as of Jul 31, 2026) and burns about $24.7M/quarter from operations, an estimated runway of 32.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENGN files for a raise →

👥 Who Owns ENGN

Insiders 0.1% Other 5%+ holders 24.3% Institutions (71 holders) 75.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
BML Investment Partners, L.P. 5%+ holder (13G) 6,669,908 9.95% 2026-05-12
Raymond Debbane 5%+ holder (13G) 6,256,662 9.34% 2026-06-30
Perceptive Advisors LLC Institution (13G, 5%+) 6,217,464 9.28% 2026-09-30
Eventide Asset Management, LLC Institution (13G, 5%+) 3,406,023 5.08% 2026-09-30
Anders Hove 5%+ holder (13G) 3,357,282 5.01% 2026-07-20
Philip Astley-Sparke
Director · +76,000 options
Insider 20,000 0.03% 2025-07-08
Matthew Ross Boyd
Chief Regulatory Officer · +295,000 options
Insider 7,500 0.01% 2025-07-08
Kathleen P. Richton
SVP, Finance and Treasurer
Insider 6,900 0.01% 2026-07-16
William Grossman
Interim Chief Medical Officer, Director · +245,000 options
Insider 5,102 0.01% 2026-09-22

Share count 67,016,316 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ENGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.